NO991407L - Legemiddelaerosolformuleringer som omfatter budesonid - Google Patents

Legemiddelaerosolformuleringer som omfatter budesonid

Info

Publication number
NO991407L
NO991407L NO991407A NO991407A NO991407L NO 991407 L NO991407 L NO 991407L NO 991407 A NO991407 A NO 991407A NO 991407 A NO991407 A NO 991407A NO 991407 L NO991407 L NO 991407L
Authority
NO
Norway
Prior art keywords
budesonide
aerosol formulations
drug aerosol
hydrofluoroalkane
lecithin
Prior art date
Application number
NO991407A
Other languages
English (en)
Other versions
NO991407D0 (no
Inventor
Nayna Govind
Philip A Jinks
Danna L Ross
Gary Ward
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10800599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO991407(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of NO991407L publication Critical patent/NO991407L/no
Publication of NO991407D0 publication Critical patent/NO991407D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet en farmasøytisk aerosolformulering, egnet for administrasjon av oral eller nasal inhalasjon, som inneholder en suspensjon av partikkelformet budesonid, hydrofluoralkandrivmiddel, eventuelt ytterligere hydrofluoralkandrivmidler, overflateaktivt middel valgt fra oleinsyre, sorbitantoleater og lecitin, og adjuvans som har en Kauri-butanolverdi på minst 10.
NO991407A 1996-09-27 1999-03-23 Legemiddelaerosolformuleringer som omfatter budesonid NO991407D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9620187.6A GB9620187D0 (en) 1996-09-27 1996-09-27 Medicinal aerosol formulations
PCT/US1997/016869 WO1998013031A2 (en) 1996-09-27 1997-09-23 Medicinal aerosol formulations comprising budesonide

Publications (2)

Publication Number Publication Date
NO991407L true NO991407L (no) 1999-03-23
NO991407D0 NO991407D0 (no) 1999-03-23

Family

ID=10800599

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991407A NO991407D0 (no) 1996-09-27 1999-03-23 Legemiddelaerosolformuleringer som omfatter budesonid

Country Status (21)

Country Link
EP (1) EP0932397B2 (no)
JP (1) JP2001501209A (no)
KR (1) KR20000048646A (no)
AR (1) AR009370A1 (no)
AT (1) ATE320246T1 (no)
AU (1) AU732985B2 (no)
BR (1) BR9712125A (no)
CA (1) CA2266431A1 (no)
CZ (1) CZ102799A3 (no)
DE (1) DE69735497T2 (no)
ES (1) ES2259447T3 (no)
GB (1) GB9620187D0 (no)
HU (1) HUP0000795A3 (no)
ID (1) ID22523A (no)
MY (1) MY130946A (no)
NO (1) NO991407D0 (no)
PL (1) PL332422A1 (no)
PT (1) PT932397E (no)
SK (1) SK38399A3 (no)
WO (1) WO1998013031A2 (no)
ZA (1) ZA978303B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EE05167B1 (et) 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
ES2222294T3 (es) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1949891A1 (en) * 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
WO2006040598A2 (en) * 2004-10-12 2006-04-20 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
ES2259915B1 (es) * 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
CN102362859A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德气雾剂制剂
CN103655473A (zh) * 2011-10-27 2014-03-26 江苏长风药业有限公司 以氢氟烷烃为抛射剂的布地奈德气雾剂制剂
CN109646400A (zh) * 2018-12-25 2019-04-19 上海信谊百路达药业有限公司 一种布地奈德吸入气雾剂及其制备方法
CN112891328A (zh) * 2021-04-12 2021-06-04 上海方予健康医药科技有限公司 一种吸入用布地奈德混悬液的制备方法
CN113768906B (zh) * 2021-10-25 2023-05-09 上海方予健康医药科技有限公司 新型糖皮质激素吸入气雾剂及药物组件

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5136107A (en) * 1990-06-04 1992-08-04 Ethyl Corporation Process for halogenating aromatic compounds
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DK0717987T3 (da) † 1991-12-18 2001-11-12 Minnesota Mining & Mfg Suspension-aerosol-formuleringer
DE4230876A1 (de) † 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
KR100321649B1 (ko) * 1993-03-17 2002-07-22 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
DE4322703A1 (de) * 1993-07-08 1995-01-12 Asta Medica Ag Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäureestern als Suspensionsstabilisatoren und Ventilschmiermittel
TW283164B (no) * 1993-09-24 1996-08-11 Du Pont
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
GB9425160D0 (en) † 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
JP4155594B2 (ja) * 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤

Also Published As

Publication number Publication date
AR009370A1 (es) 2000-04-12
CZ102799A3 (cs) 1999-07-14
EP0932397B1 (en) 2006-03-15
AU4492697A (en) 1998-04-17
JP2001501209A (ja) 2001-01-30
PT932397E (pt) 2006-07-31
HUP0000795A3 (en) 2000-09-28
ZA978303B (en) 1999-03-15
WO1998013031A2 (en) 1998-04-02
GB9620187D0 (en) 1996-11-13
CA2266431A1 (en) 1998-04-02
DE69735497T2 (de) 2006-08-24
EP0932397A2 (en) 1999-08-04
PL332422A1 (en) 1999-09-13
EP0932397B2 (en) 2014-04-02
MY130946A (en) 2007-07-31
SK38399A3 (en) 1999-09-10
ATE320246T1 (de) 2006-04-15
ES2259447T3 (es) 2006-10-01
DE69735497D1 (de) 2006-05-11
NO991407D0 (no) 1999-03-23
BR9712125A (pt) 1999-08-31
ID22523A (id) 1999-10-28
HUP0000795A2 (hu) 2000-08-28
WO1998013031A3 (en) 1998-08-27
AU732985B2 (en) 2001-05-03
KR20000048646A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
MY130946A (en) Medicinal inhalation aerosol formulations containing budesonide
NO20065102L (no) Medikamenter
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
HUP9802278A2 (hu) Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban
AU4260496A (en) Propellant mixture for aerosol formulation
GB2332372B (en) Pharmaceutical aerosol compositions
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
MY108748A (en) Medicaments
CA2381329A1 (en) Medicaments
ATE114112T1 (de) Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
NO944526L (no) Medisinsk aerosolformulering
CA2416403A1 (en) A medicinal aerosol formulation
YU59192A (sh) Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
AR018183A1 (es) Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la r
HUP0002691A2 (hu) Ciklezonid tartalmú gyógyászati aeroszol termékek
DE69533190D1 (de) Behandlung von pulmonaler vasokonstriktion und asthma
MX9707238A (es) Formulaciones en aerosol de butixocort.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application